Stay updated on RMC-6236 in RAS Mutant Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the RMC-6236 in RAS Mutant Solid Tumors Clinical Trial page.

Latest updates to the RMC-6236 in RAS Mutant Solid Tumors Clinical Trial page
- Check6 days agoChange DetectedThe page’s footer revision tag was updated to v3.5.5, signaling a minor page revision. This change typically reflects small content or formatting updates rather than alterations to study data.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check20 days agoChange DetectedThe locations section has been expanded to add new recruitment sites, bringing the total to 21 locations across multiple states. New sites include Virginia Mason Medical Center in Seattle, WA, along with several other participating centers.SummaryDifference1%

- Check28 days agoChange DetectedA new NEJM publication citation for Daraxonrasib in previously treated advanced RAS-mutant pancreatic cancer has been added, and the page revision tag was updated from v3.5.3 to v3.5.4.SummaryDifference0.1%

- Check42 days agoChange DetectedThe page now displays Revision: v3.5.3, replacing the previous Revision: v3.5.2. This reflects a minor version update to the page.SummaryDifference0.0%

- Check56 days agoChange DetectedFooter revision label updated to Revision: v3.5.2. The previous Revision: v3.5.0 entry was removed.SummaryDifference0.0%

- Check85 days agoChange DetectedAdded revision v3.5.0 and removed revision v3.4.3.SummaryDifference0.0%

Stay in the know with updates to RMC-6236 in RAS Mutant Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the RMC-6236 in RAS Mutant Solid Tumors Clinical Trial page.